Treatment of Advanced Medullary Thyroid Carcinoma with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine: a Single-Center Experience
Experimental and Clinical Endocrinology & Diabetes, 07/11/2011Deutschbein T et al.
Although objective tumor response rates were low, the cyclophosphamide, vincristine, and dacarbazine (CVD) regimen allowed disease stabilization for a substantial period of time and had acceptable toxicity. After initial surgery, chemotherapy may therefore be considered as a medical treatment option.
9 patients (5 males; age 55.0±4.0 years) with MTC were enrolled.
Prior to chemotherapy, progressive disease was established in all patients by use of WHO criteria.
On day 1 of each cycle, patients started with cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, and dacarbazine 600 mg/m2; on day 2, patients received dacarbazine alone (600 mg/m2).
Treatment cycles were repeated at 21–day intervals and 6 cycles were planned for each patient.
The standard imaging procedure was computed tomography, and the primary end point was the objective tumor response rate.
After chemotherapy, patients were followed up until progression.
9 patients underwent a total of 57 cycles (mean 6.3±0.3 cycles).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.